Dynavax Technologies Corp. (NASDAQ:DVAX)’s share price was up 2.4% during trading on Wednesday . The stock traded as high as $17.50 and last traded at $17.26, with a volume of 267,115 shares changing hands. The stock had previously closed at $16.85.

Several equities analysts have commented on DVAX shares. Cowen and Company reissued a “buy” rating and set a $60.00 price objective on shares of Dynavax Technologies Corp. in a research report on Thursday, April 28th. Zacks Investment Research raised Dynavax Technologies Corp. from a “sell” rating to a “hold” rating in a research report on Friday, July 8th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Dynavax Technologies Corp. presently has a consensus rating of “Hold” and an average target price of $32.20.

The firm’s 50-day moving average is $15.56 and its 200 day moving average is $16.88. The company’s market capitalization is $619.80 million.

Dynavax Technologies Corp. (NASDAQ:DVAX) last released its earnings results on Friday, August 5th. The biopharmaceutical company reported ($0.75) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.68) by $0.07. The firm earned $2.65 million during the quarter, compared to analysts’ expectations of $1.58 million. During the same quarter in the prior year, the company posted ($0.80) earnings per share. The business’s revenue was up 70.8% on a year-over-year basis. Analysts anticipate that Dynavax Technologies Corp. will post ($2.96) EPS for the current fiscal year.

A hedge fund recently raised its stake in Dynavax Technologies Corp. stock. Swiss National Bank increased its stake in shares of Dynavax Technologies Corp. (NASDAQ:DVAX) by 5.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 48,528 shares of the biopharmaceutical company’s stock after buying an additional 2,600 shares during the period. Swiss National Bank owned about 0.13% of Dynavax Technologies Corp. worth $1,172,000 at the end of the most recent quarter.

Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company. The Company uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. Its development programs are focused on vaccines and cancer immunotherapy. The Company’s lead vaccine product candidate is HEPLISAV-B, an investigational adult hepatitis B vaccine, which combines its TLR9 agonist adjuvant and recombinant hepatitis B surface antigen (rHBsAg).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.